Article
Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study.
BMC medicine - 8 Jan 2023
Shi Yuankai, Zhou Jianying, Zhao Yanqiu, Zhu Bo, Zhang Liangming, Li Xingya, Fang Jian, Shi Jianhua, Zhuang Zhixiang, Yang Sheng, Wang Donglin, Yu Huiqing, Zhang Longzhen, Zheng Rongsheng, Greco Michael, Wang Tingting
Abstract excerpt
BACKGROUND: Rezivertinib (BPI-7711) is a novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). This phase IIa study was part of a phase I/IIa study (NCT03386955), aimed to evaluate the efficacy and safety of rezivertinib as the first-line treatment for patients with locally advanced or metastatic/recurrent EGFR mutated non-small cell lung cancer (NSCLC). METHODS: Patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.